Core Viewpoint - Zhuozheng Medical has successfully transitioned from loss to profit, marking a significant milestone with its listing on the Hong Kong Stock Exchange, showcasing a perfect growth trajectory for a private mid-to-high-end medical enterprise [3][4]. Group 1: Company Overview - Zhuozheng Medical officially listed on the Hong Kong Stock Exchange with a share price set at HKD 59, issuing 4.75 million shares and raising a total of HKD 285 million, with a net amount of HKD 209 million after expenses [3]. - The company has established a service network across 10 economically developed cities in China, operating 19 medical service institutions, including 17 clinics and 2 hospitals [3][4]. Group 2: Financial Performance - The company has shown consistent improvement in financial performance, with revenue increasing from CNY 473 million in 2022 to CNY 959 million in 2024, and gross profit rising from CNY 43.98 million to CNY 226 million during the same period [4]. - Zhuozheng Medical achieved a profit of CNY 80.23 million in 2024, marking its first profitable year, and continued this growth trend in the first eight months of 2025 with revenue of CNY 696 million and a profit of CNY 83.21 million [4]. Group 3: Market Position - According to Frost & Sullivan, Zhuozheng Medical ranks third among private mid-to-high-end comprehensive medical service providers in China, holding a market share of 2.0% based on 2024 revenue [4]. - The company stands out in a highly fragmented industry due to its extensive city coverage and large patient base, ranking first in the number of covered cities and second in patient visits among paid patients as of December 31, 2024 [4].

Core Viewpoint - The rapid development of artificial intelligence and biomedicine is leading to unprecedented changes in the healthcare service industry [2][6]. IPO Details - Zhuozheng Medical Holdings Limited is set to be listed on the Hong Kong Stock Exchange on February 6, 2026, under the stock code "2677" [2]. - The company issued a total of 4,750,000 shares, raising a total of HKD 284 million, with a subscription rate of 2730.73 times for the public offering and 5.79 times for the international offering [2]. - Notable cornerstone investors include He Xiaopeng, CEO of Xiaopeng Motors, who subscribed for USD 1 million, and other tech companies with AI attributes [3]. Market Position and Growth - Zhuozheng Medical ranks first and second among private high-end comprehensive medical service institutions in terms of the number of cities covered and the number of paid patient visits in 2024 [9]. - The company has a strong reputation based on service quality, with high net promoter scores (NPS) of 81.1, 86.4, 85.9, and 87.6 from 2022 to 2025 [9]. Membership and Customer Retention - As of August 31, 2025, Zhuozheng Medical had 116,542 member accounts, with renewal rates increasing from 42% in 2022 to 67% in 2025 [11]. - The patient return rate also improved from 75.7% in 2022 to 82.7% in 2025, indicating strong customer loyalty [11]. Business Model - Zhuozheng Medical adopts a Costco-like model in the healthcare sector, focusing on a membership system and high-value services to drive growth [11][13]. - The company offers a range of services that cater to high-frequency health needs, allowing for longer customer retention periods and higher consumption frequency [13]. Financial Performance - Zhuozheng Medical achieved revenue growth from CNY 473 million in 2022 to CNY 959 million in 2024, with a compound annual growth rate (CAGR) of 42.2% [14]. - The gross profit also increased significantly, from CNY 44 million in 2022 to CNY 226 million in 2024, with a CAGR of 126.7% [14]. - The company turned profitable in 2024, with an adjusted net profit of approximately CNY 10.45 million in the first eight months of 2025 [14]. Investor Support - Zhuozheng Medical has received investments from notable firms such as Tencent, Matrix Partners, Tiantu Capital, and others, indicating strong institutional support [16][17]. - Investors believe that the company is well-positioned to meet the growing demand for high-quality healthcare services in China [17][18].

Investment Rating - The report suggests a cautious subscription for the company [1] Core Insights - The company is a private healthcare service provider in China, focusing on the mid-to-high-end medical service market, targeting affluent individuals with a disposable income exceeding RMB 200,000 [2] - The private mid-to-high-end healthcare service market in China is expected to grow significantly, with total revenue projected to increase from RMB 193 billion in 2020 to RMB 426 billion by 2024, reflecting a compound annual growth rate (CAGR) of 21.9% [3] - The company operates 19 healthcare facilities across major Chinese cities, including 17 clinics and 2 hospitals, and holds a market share of 2.0% in the private mid-to-high-end healthcare service sector [3] Financial Performance - The company's revenue for 2023 and 2024 is projected to be RMB 690 million and RMB 959 million, respectively, with a net profit of RMB 802 million expected in 2024 [4] - For the first eight months of 2025, the company has already achieved a revenue of RMB 696 million, representing a year-on-year growth of 14.0% [4] - The estimated market capitalization post-IPO is between HKD 37.15 billion and HKD 42.88 billion, with a price-to-earnings (PE) ratio of 26-31 times, indicating a relatively high valuation [4]

Investment Rating - The report suggests a cautious subscription for the company [1][4]. Core Insights - The company is a private healthcare service provider in China, focusing on the mid-to-high-end medical service market, targeting affluent individuals with a disposable income exceeding RMB 200,000 [2]. - The private mid-to-high-end healthcare service market in China is expected to grow significantly, with total revenue projected to increase from RMB 193 billion in 2020 to RMB 426 billion by 2024, representing a compound annual growth rate (CAGR) of 21.9% [3]. - The company operates 19 healthcare facilities across major Chinese cities, including 17 clinics and 2 hospitals, and is positioned as the third-largest private mid-to-high-end healthcare service provider in China with a market share of 2.0% [2][3]. Financial Performance - The company's revenue for 2023 and 2024 is projected to be RMB 690 million and RMB 959 million, respectively, with a net profit of RMB 80.2 million expected in 2024 [4]. - For the first eight months of 2025, the company has already achieved a revenue of RMB 696 million, reflecting a year-on-year growth of 14.0% [4]. - The estimated market capitalization post-IPO is between HKD 3.715 billion and HKD 4.288 billion, with a price-to-earnings (PE) ratio of 26-31 times, indicating a relatively high valuation considering the company's growth potential [4].

Core Viewpoint - Zhuozheng Medical Holdings Limited is a leading private mid-to-high-end comprehensive medical service provider in China, focusing on affluent customers seeking personalized healthcare services [2]. Group 1: Company Overview - Established in 2012, Zhuozheng Medical targets the mid-to-high-end medical service market, catering to affluent individuals with strong purchasing power [2]. - The company operates a network of 19 medical service institutions across major Chinese cities, including Shenzhen, Guangzhou, Beijing, and others, as well as clinics in Singapore and Malaysia [2]. Group 2: Market Position - According to Frost & Sullivan, Zhuozheng Medical ranks first in the number of cities covered and second in the number of paid patient visits among private mid-to-high-end comprehensive medical service providers in China as of 2024 [2]. Group 3: Customer Satisfaction and Marketing - Zhuozheng Medical's reputation is built on service quality, with a high Net Promoter Score (NPS) of 87.6 in the first eight months of this year, indicating strong patient satisfaction and word-of-mouth referrals [3][4]. - The company has a growing membership base, with 116,542 members as of August 31, 2025, and a renewal rate increasing from 42% in 2022 to 67% in 2024 [4]. Group 4: Financial Performance - Zhuozheng Medical's revenue has shown significant growth, with figures of 473 million, 690 million, and 959 million yuan for the years 2022 to 2024, respectively, and 696 million yuan in the first eight months of this year [4]. - The company achieved profitability in 2024, with an adjusted net profit of approximately 10.45 million yuan in the first eight months of this year [5]. Group 5: Investment and IPO Plans - Prior to the IPO, Tencent held a 19.39% stake in Zhuozheng Medical, making it the largest institutional investor [6]. - The net proceeds from the IPO will be used for developing a medical AI talent pool, strategic collaborations, upgrading existing facilities, establishing new institutions, and potential acquisitions in key cities [6].

Core Viewpoint - 卓正医疗控股有限公司 is focusing on the high-end medical service market in China, targeting affluent consumers who prefer personalized healthcare services, and is preparing for its listing on the Hong Kong Stock Exchange [1][4]. Company Overview - 卓正医疗 is the third-largest private high-end comprehensive medical service provider in China, with a market share of 2.0% based on projected revenues for 2024 [4]. - The company operates a network of 19 medical service institutions across major Chinese cities and has additional clinics in Singapore and Malaysia [5]. Market Analysis - The private high-end medical service market in China is projected to grow from RMB 193 billion in 2020 to RMB 426.3 billion by 2024, reflecting a compound annual growth rate (CAGR) of 21.9%. It is expected to continue growing at a CAGR of 14.3% from 2024 to 2029, reaching RMB 831.4 billion by 2029 [4]. - Private high-end medical service institutions are expected to account for approximately 66.5% of the total revenue in the high-end medical service market in China by 2024 [4]. Business Model - 卓正医疗 employs a family healthcare model that integrates both in-person and online medical services, enhancing patient satisfaction and facilitating cross-specialty referrals [6]. - The company has a structured talent development framework to attract and retain qualified medical professionals, with 387 full-time doctors averaging about 15 years of experience [6]. Financial Performance - Revenue figures for 卓正医疗 from 2022 to 2024 are as follows: RMB 473.2 million in 2022, RMB 690.4 million in 2023, and RMB 958.6 million in 2024, indicating a consistent upward trend [7]. - The company recorded net losses of RMB 222 million in 2022 and RMB 353 million in 2023, but achieved a profit of approximately RMB 80.2 million in 2024 [6][7].